Eli Lilly & Co. vs. ARS Pharmaceuticals, Inc. Common Stock
Eli Lilly & Co. (LLY) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| LLY | SPRY | |
|---|---|---|
| Market Cap | $1.02 trillion | $558.89 million |
| Revenue (TTM) | $79.67 billion | $116.93 million |
| Net Income (TTM) | $26.71 billion | $-215,432,000 |
LLY leads on 3 of 3 size & scale factors.
Valuation
| LLY | SPRY | |
|---|---|---|
| P/E Ratio | 38.58 | — |
| Price / Book | 30.24 | 44.67 |
| Price / Sales | 12.86 | 4.78 |
LLY and SPRY split the valuation factors evenly.
Profitability
| LLY | SPRY | |
|---|---|---|
| Net Margin | 33.53% | -184.24% |
| Return on Equity | 78.84% | -1721.80% |
LLY leads on 2 of 2 profitability factors.
Dividend
| LLY | SPRY | |
|---|---|---|
| Dividend Yield | 0.60% | — |
| Payout Ratio | 23.23 | — |
LLY and SPRY split the dividend factors evenly.
Risk & Sentiment
| LLY | SPRY | |
|---|---|---|
| Short Interest | 1.29% | 0.82% |
SPRY leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, SPRY overview, SPRY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.